Abstract:Importance Cognitive impairment contributes significantly to clinical outcome and level of function in individuals with psychotic disorders. These impairments are present already at psychosis onset at a group level; however, the question of heterogeneity in cognitive function among patients has not been systematically investigated. Objective To provide an updated quantification of cognitive impairment at psychosis onset before patients receive potentially confounding antipsychotic treatment, and to investigate variability in cognitive function compared with healthy controls. Data Sources In this systematic review and meta-analysis, PubMed articles were searched up to September 15, 2022. Study Selection Original studies reporting data on cognitive function in antipsychotic drug–naive patients with first-episode psychosis (FEP) were included. Data Extraction and Synthesis Data were independently extracted by 2 researchers. Cognitive tasks were clustered according to 6 domains of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery and the domain of executive function. Random-effects model meta-analyses of mean differences and coefficient of variation ratios (CVRs) were performed, as well as meta-regressions, assessment of study quality, and publication bias. Main Outcomes and Measures The main outcome measure was Hedges g for mean differences in cognition and CVR for within-group variability. Results Fifty studies were included in the analysis with a total of 2625 individuals with FEP (mean [SD] age, 25.2 [3.6] years, 60% male; 40% female) and 2917 healthy controls (mean [SD] age, 26.0 [4.6]; 55% male; 45% female). In all cognitive domains, the FEP group displayed significant impairment compared with controls (speed of processing: Hedges g = −1.16; 95% CI, −1.35 to −0.98; verbal learning: Hedges g = −1.08; 95% CI, −1.28 to −0.88; visual learning: Hedges g = −1.05; 95% CI, −1.27 to −0.82; working memory: Hedges g = −1.04; 95% CI, −1.35 to −0.73; attention: Hedges g = −1.03; 95% CI, −1.24 to −0.82; reasoning/problem solving: Hedges g = −0.90; 95% CI, −1.12 to −0.68; executive function: Hedges g = −0.88; 95% CI, −1.07 to −0.69). Individuals with FEP also exhibited a larger variability across all domains (CVR range, 1.34-1.92). Conclusions and Relevance Results of this systematic review and meta-analysis identified cognitive impairment in FEP before the initiation of antipsychotic treatment, with large effect sizes. The high variability within the FEP group suggests the need to identify those individuals with more severe cognitive problems who risk worse outcomes and could benefit the most from cognitive remediation.

Cognitive Effects of Atypical Antipsychotic Drugs in First-Episode Drug-Naïve Schizophrenic Patients.

Neurocognitive Effects of Atypical Antipsychotics in Patients with First-Episode Schizophrenia.

The influences of olanzapine and risperidone on cognitive function and P300potentials in first-episode schizophrenia

Neurocognitive Effects of First- and Second-Generation Antipsychotic Drugs in Early-Stage Schizophrenia: A Naturalistic 12-Month Follow-Up Study

Eff Ectiveness of Antipsychotic Drugs in Fi Rst-Episode Schizophrenia and Schizophreniform Disorder : an Open Randomised Clinical Trial

Short-term Effects of Antipsychotic Treatment on Cerebral Function in Drug-Naive First-Episode Schizophrenia Revealed by “resting State” Functional Magnetic Resonance Imaging

Risperidone-induced Topological Alterations of Anatomical Brain Network in First-Episode Drug-Naive Schizophrenia Patients: a Longitudinal Diffusion Tensor Imaging Study

Neurocognitive Effects of Atypical and Conventional Antipsychotic Drugs in Early-Stage Schizophrenia: A Naturalistic 12-Month Follow-Up Study

Effects Of Olanzapine, Quetiapine, And Risperidone On Neurocognitive Function In Early Psychosis: A Randomized, Double-Blind 52-Week Comparison

Cognitive Function in First-Episode Adolescent-Onset Schizophrenia Before and after Treatment

Cognitive function changes with risperidone monotherapy and their relationship to psychotic symptoms in treatment-na?ve first-episode schizophrenia patients

A Randomized Controlled Trial of Olanzapine Improving Memory Deficits in Han Chinese Patients with First-Episode Schizophrenia.

Short Term Neurocognitive Effects of Treatment with Ziprasidone and Olanzapine in Recent Onset Schizophrenia

Differential Effects of Different Antipsychotic Drugs on Cognitive Function in Patients with Chronic Schizophrenia

P03-367 - Neurocognitive effects of atypical and conventional antipsychotic drugs in early-stage schizophrenia: a naturalistic 12-month follow-up study

The Effect of Aripiprazole on Cognitive Function、Executive Function and Quality of Life in the First-Episode Schizophrenia

6-Month Follow-Up on Efficacy of Three Kinds of Atypical Antipsychotics in the First Episode Patients with Schizophrenia

Olanzapine and Haloperidol in First Episode Psychosis: Two-year Data

Antipsychotic Drugs and Cognitive Function: A Systematic Review and Pairwise Network Meta-Analysis

Cognitive Function and Variability in Antipsychotic Drug–Naive Patients With First-Episode Psychosis

Comparative Efficacy and Safety of Atypical and Conventional Antipsychotic Drugs in First-Episode Psychosis: a Randomized, Double-Blind Trial of Olanzapine Versus Haloperidol.